Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer

Author Info

Gesa Isensee Beat Thürlimann

Corresponding Author

Beat Thürlimann
Kantonsspital St. Gallen, St. Gallen, Switzerland

A B S T R A C T

We describe a case of a 55-year-old woman with a rare metastatic micropapillary low-grade serous ovarian cancer who had been heavily pretreated. A KRAS-mutation and c-MYC-amplification were detected, and we initiated a therapy with the CDK4/6- inhibitor Palbociclib in combination with the steroidal aromatase inhibitor exemestane. We postulated that the combination therapy leads to a blocking of the c-MYCamplification-activated cell cycle, proliferation, and inhibition of apoptosis, further enhanced by other oncogenes like mutated RAS. This therapy showed a good and lasting response representing a new opportunity for therapy in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.

Article Info

Article Type

Case Report

Publication history

Received: Tue 08, Dec 2020
Accepted: Tue 22, Dec 2020
Published: Thu 31, Dec 2020

Copyright

© 2023 Beat Thürlimann. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.CROGR.2020.03.04